Trial Profile
A prospective study to explore the relationship between SPARC expression and efficacy of nab-paclitaxel as second-line chemotherapy for advanced gastric cancer (SYNAPSE study)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Nov 2020
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Therapeutic Use
- Acronyms SYNAPSE
- 16 Nov 2020 Status changed from active, no longer recruiting to discontinued.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 13 Aug 2014 New trial record